Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317994 | 0.77 | RAB9A (0.40) | ABL1CYP3A4SMN1; SMN2BACE1CA1 | |
| SCHEMBL30507123 | 0.77 | RAB9A (0.40) | ABL1CYP3A4SMN1; SMN2BACE1CA1 | |
| SCHEMBL25317922 | 0.75 | CYP4F2 (0.35) | ABL1CYP3A4SMN1; SMN2NR1I2TIPARP | |
| SCHEMBL25934672 | 0.70 | RAB9A (0.40) | CYP3A4BACE1 | |
| SCHEMBL25903116 | 0.70 | TDP1 (0.41) | SMN1; SMN2GAA | |
| SCHEMBL26023163 | 0.68 | MMP13 (0.40) | CYP3A4SMN1; SMN2CA1CA2 | |
| SCHEMBL25313592 | 0.68 | RAB9A (0.38) | CYP3A4SMN1; SMN2 | |
| SCHEMBL30506855 | 0.68 | RAB9A (0.38) | CYP3A4SMN1; SMN2 | |
| SCHEMBL26022220 | 0.66 | TDP1 (0.39) | SMN1; SMN2GAA | |
| SCHEMBL25316966 | 0.63 | CYP4F2 (0.32) | CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |